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radiotherapy alone. Direct and indirect costs were derived from published peer-
reviewed literature or government data. Utilities were obtained from a previously
published cost-utility analysis of temozolomide and carmustine wafers in newly
diagnosed glioblatoma. Univariate and threshold sensitivity analyses were con-
ducted on all survival data, input costs, utilities, and other important parameters.
RESULTS: The addition of temozolomide to the standard radiotherapy regimen
was associated with a base-case incremental cost-effectiveness ratio of $154,933
per quality-adjusted life-year. This is considerably higher than the only other com-
parable estimate, which assumed the perspective of the UK National Health Ser-
vice and did not include indirect costs. The model was most sensitive to the utility
associated with the use of temozolomide during the maintenance phase of stable
disease treatment. CONCLUSIONS: The base-case incremental cost-effectiveness
ratio lies just beyond a willingness-to-pay threshold of $150,000 per quality-ad-
justed life-year. However, sensitivity analysis revealed numerous plausible scenar-
ios that produced lower estimates. Notably, a 10% increase in the utility associated
with stable disease treatment produced an estimate of $120,743 per quality-ad-
justed life-year. Given these results and the lack of alternative treatments for glio-
blastoma, we conclude that temozolomide’s use in this setting is not definitively
cost-effective. However, better estimates of relevant health state utilities could
greatly improve cost-effectiveness models for glioblastoma treatments.
PCN79
COST EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION FOR THE
PREVENTION OF CERVICAL CANCER IN URBAN REGIONS OF CHINA
Ross KD1, Cui L2, Thomas DB3
1University of Arkansas at Little Rock, Little Rock, AR, USA, 2University of Washington, Seattle,
WA, USA, 3Fred Hutchinson Cancer Center, Seattle, WA, USA
OBJECTIVES: To determine the costs, outcomes and level of cost-effectiveness
associated with HPV vaccination in urban China. METHODS: A Markov model of
HPV vaccination in urban China is used to follow hypothetical females from age 12
to age 92. The individuals in the model are assumed to be vaccinated at age 12 and
the rates of HPV infection, squamous intraepithelial lesions, cervical cancer and
death are measured on an annual basis for 80 years. All costs and outcomes are
discounted. RESULTS: In our base case analysis, the administration of HPV vaccine
could reduce cervical cancer rate by 65%. In ourmodel, HPV vaccination is found to
be cost-saving. The implementation of HPV vaccination results in an increase of 0.6
QALYs over the lifetime of each individual. The total lifetime discounted costs with
vaccination are $766 dollars per individual lower than the total costs without vac-
cination. Under all scenarios examined in our sensitivity analysis, the total costs
with vaccination are reduced when compared to current practice with an increase
in QALYs as well. CONCLUSIONS: Compared to current practice in China, which
does not include cervical cancer screening, HPV vaccination appears to be cost-
saving. China has a coverage rate of 95% for its childhood immunization program.
Incorporating HPV vaccination into this program could likely be done with a min-
imal amount of effort. Our results provide strong evidence for the implementation
of HPV vaccination programs in urban China.
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OBJECTIVES: The purpose of this research was to determine the cost-effectiveness
of sunitinib in terms of the RF health care system. In this research, the comparisons
of costs and effectiveness with patients treated by sunitinib, IFN-, sorafenib and
bevacizumab with IFN- were studied, based on the RF health care system
conditions.METHODS: In this Pharmacoeconomic research the cost-effectiveness
analysis (CEA) and cost-utility analysis (CUA) were studied. The results were esti-
mated in life years before the disease progression (PfLYs) and prolonged life years
(LYs)within CEA andquality-adjusted life-years (QALYs)within CUA. The results of
these analyses were illustrated in incremental cost-effectiveness rate (ICER) and
cost-utility rate (ICUR). The cost-utility analysis was chosen as the main analytical
method, because sunitinibwas supposed not only to affect survivability but quality
of life as well. RESULTS: The data of the research illustrates that sunitinib usage as
a first-line drug for mRCC patients provides a significant health improvement in
terms of PFS and OS, expressed in ICER index, equal to 3,742,060 rub and 955 451 for
a saved life year, and ICUR index, equal to 6,787,955 rub and 2,912,714 rub for QALY
in comparison with IFN- and sorafenib respectively. High values of these indexes
are mainly caused by high cost of sunitinib and relatively low cost of healthcare
resources in Russian Federation. In comparison with bevacizumab with IFN-,
sunitinib is dominant, providing better efficacy with lower cost. CONCLUSIONS:
These results suggest that sunitinib is a cost-effective alternative to sorafenib,
bevacizumab with IFN-, and sorafenib as a first-line treatment of mRCC.
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OBJECTIVES: To evaluate the health-related quality of life (HRQOL) and to compare
direct medical, non-medical and indirect cost of stage III colorectal cancer(CRC)
patients receiving either capecitabine-based or 5-FU/LV-based adjuvant treat-
ments from societal perspective. METHODS: An observational follow-up study to
collect HRQOL and cost data from stage III CRC patients were conducted in 12
hospitals from 2008 to 2010. A total of 535 patients were invited to complete ques-
tionnaires during the study period: at study baseline (Q0), at 3 months after the
initial adjuvant treatment (Q3), and at 1 month after treatment had finished (Q7)
using the EORTC QLQ-C30 and QLQCR-38 questionnaires. Cost data were obtained
fromNational Health Insurance Research Database (NHIRD), patient questionnaire
(Q3) and productivities loss from Manpower Utilization Survey. 66% of patients
completed the questionnaire as per protocol and their data were the basis for
further analysis. Propensity score matching (PSM) method was used to reduce
selection bias and to avoid endogenous problems by matching variables, i.e. age,
gender, location of tumor, marital status, education, work and the number of co-
morbidities between two groups. After PSM, a total of 239 patients were analyzed.
RESULTS: In capecitabine-based treatment, Physical, Role, Emotional, Social,
Global Health status, Body Image, Future perspective Functioning, Fatigue, Pain,
Diarrhea, Stoma-related problem, and Weight loss Symptoms were all improved
from Q0 to Q3 and Q0 to Q7. In 5-FU/LV-based treatment, Physical, Role, Social,
Global health status Functioning, GI tract and Weight loss Symptoms also im-
proved. Total directmedical, direct non-medical, and indirect cost of capecitabine-
based and 5-FU/LV-based treatment were NT$29,452 (USD $982) and NT$55,200
(USD $1,840), respectively.CONCLUSIONS:This real-life study shows that adjuvant
chemotherapy has no negative impact on HRQOL during study period. Capecit-
abine-based treatment performs better in most functioning aspects of HRQOL and
is cost-saving in direct and indirect resources utilization from societal perspective.
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OBJECTIVES: To assess the cost-effectivness of lenalidomide in treatment of the
second and third lines of multiple myeloma in the Russian Federation.METHODS:
We developed an economic model of multiple myeloma disease to calculate the
cost of diagnosis and treatment of second and third-line therapy of lenalidomide
and bortezomib. The efficacy of drugs (time to progression- TTP)was obtained from
clinical trials: MM - 009/-010 for lenalidomide; APEX for bortezomib. TTP for lena-
lidomide was 21.2 months and for bortezomib - 16.4 months. Medical care costs
were estimated from the standard of multiple myeloma treatment, which was
developed and published by Ministry of public health. RESULTS: A CER of lenalido-
mide in the second line therapy was 468,110,84 RUB (11,529,82 €) which is lower
then use of bortezomib in the second line therapy 605 118,89 RUB (14,904,4 €).
CONCLUSIONS: Application of lenalidomide in second-line therapy of multiple
myeloma is dominated alternative of treatment.
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OBJECTIVES: Formany years, the backbone of cancer treatment has been the use of
cytotoxic agents. There has been an emergence of new drugs, however, that are
more specific to the target. Some of these agents have resulted in a prolongation of
survival and even clinical cures in some cancers. In order to compare and contrast
the costs and benefits of these new drug therapies, a descriptive evaluation across
seven major tumour types was undertaken. METHODS: A literature search was
conducted from 2000 to 2011 to identify randomized trials of novel therapies in
breast, lung, colorectal, kidney, lymphoma, multiple myeloma and chronic my-
elogenous leukemia. Clinical outcomes in terms of progression free (PFS) and over-
all survival (OS) benefit were extracted. Economic data in terms of cost per month
of therapy was obtained from a U.S. cancer clinic. RESULTS: Approximately 22
novel therapies were approved across the seven cancers. Four of the 22 (18%) were
used with a curative intent while the remainder were used in the palliative setting
(n18). Ten of these 18 (56%) latter agents also demonstrated an OS benefit. The
median month cost for novel therapies used with a curative intent and those with
a survival benefit in the palliative setting were $5450 and $6450 respectively. In
contrast, the median monthly cost for drugs that did not offer either of these
benefits was $7900. Of the agents identified, imatinib, lenalidomide, rituximab and
trastuzumab provided the greatest magnitude of benefit for both PFS and OS and
would be considered major clinical advances. CONCLUSIONS: Approximately 64%
of novel drugs approved over the past 11 years are used with a curative intent or
provide a survival benefit in the palliative care setting. Themonthly cost for agents
not providing these benefits, however,was higher, indicating a disconnect between
efficacy and cost.
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OBJECTIVES: To identify which is the chemotherapy scheme alternative that
minimizes costs in the 1st line treatment of Metastatic Colorectal Cancer
(mCRC) in Mexico.METHODS: Costminimization comparing different chemother-
apy schemes for mCRC: XELOX (CapecitabineOxaliplatin), FOLFOX-4
(OxaliplatinFluorouracilfolinic acid), FOLFOX-6 (Oxaliplatin Fluorouracil fo-
linic acid) and FOLFIRI (IrinotecanFluorouracilfolinic acid). It was performed a
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